Repligen Receives FDA Approval to Initiate Phase 1 Clinical Trial of Potential Treatment for Spinal Muscular Atrophy

Repligen Corporation RGEN announced today that it has received approval from the Food and Drug Administration to initiate a Phase 1 clinical trial of RG3039, a potential treatment for Spinal Muscular Atrophy (SMA). SMA is an inherited neurodegenerative disease in which a defect in the SMN1 (“survival motor neuron”) gene results in low levels of the protein SMN and leads to progressive damage to motor neurons, loss of muscle function and, in many patients, early death. This is a double-blind study to evaluate the pharmacokinetic and safety profile of escalating doses of RG3039 in up to 40 healthy volunteers. This will be the first clinical trial of a novel drug specifically designed to treat SMA and the first treatment approach which seeks to increase levels of the protein SMN. “We are very pleased to have received approval to initiate human clinical trials with RG3039,” stated Walter C. Herlihy, President and Chief Executive Officer of Repligen Corporation. “RG3039 targets the core deficit of SMA and if this therapeutic approach is successful, it has the potential to arrest or slow disease progression and significantly improve patients' lives.”